Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Diabetes

Mounjaro™ (tirzepatide) injection

Approval Date: May 2022

Note: New Product

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Farxiga (dapgliflozin) tablets

Approval Date: Feb 2022

Note: First-Time Generic

A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.

Rezvoglar (insulin glargine-aglr) injection

Approval Date: Dec 2021

Note: New Product, Biosimilar

Indicated to improve glycemic control for type 1 and 2 diabetes

Jentadueto® (linagliptin and metformin hydrochloride) tablets

Approval Date: Aug 2021

Note: First-Time Generic

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

Tradjenta® (linagliptin) tablets

Approval Date: Aug 2021

Note: First-Time Generic

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

Januvia® (sitagliptin) tablets

Approval Date: Sep 2021

Note: New Product

A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise

Semglee® (insulin glargine-yfgn) injection for subcutaneous use

Approval Date: Jul 2021

Note: New Product

This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)

ZEGALOGUE® (DASIGLUCAGON) INJECTION FOR SUBCUTANEOUS USE

Approval Date: Mar 2021

Note: New Product

For the treatment of severe hypoglycemia in diabetic patients

Medication Name

Approval Date

Category

Description

Mounjaro™ (tirzepatide) injection

May 2022

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Note: New Product

Farxiga (dapgliflozin) tablets

Feb 2022

A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.

Note: First-Time Generic

Rezvoglar (insulin glargine-aglr) injection

Dec 2021

Indicated to improve glycemic control for type 1 and 2 diabetes

Note: New Product, Biosimilar

Jentadueto® (linagliptin and metformin hydrochloride) tablets

Aug 2021

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

Note: First-Time Generic

Tradjenta® (linagliptin) tablets

Aug 2021

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

Note: First-Time Generic

Januvia® (sitagliptin) tablets

Sep 2021

A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise

Note: New Product

Semglee® (insulin glargine-yfgn) injection for subcutaneous use

Jul 2021

This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)

Note: New Product

ZEGALOGUE® (DASIGLUCAGON) INJECTION FOR SUBCUTANEOUS USE

Mar 2021

For the treatment of severe hypoglycemia in diabetic patients

Note: New Product
lockenvelopephone-handsetmenucross-circle